Global Diphtheria, Pertussis, and Tetanus (DTaP) Vaccine Market is expected to grow at a CAGR of 6.91% during the forecast period from 2019-2026

A new research report published by Fior Markets with the title Diphtheria, Pertussis, and Tetanus (DTaP) Vaccine Market by Product Type (Daptacel, Infanrix, Kinrix, Pediarix, Others), Disease Type, End User, Regions”, and Global Forecast 2019-2026.

As per the report, global diphtheria, pertussis, and tetanus (DTaP) vaccine market is expected to grow from USD 2.97 Billion in 2018 to USD 5.07 Billion by 2026, at a CAGR of 6.91% during the forecast period from 2019-2026. The North America region dominated the global DTaP vaccine market with a market share of 39.56%in 2018. However the Asia Pacific region is expected to grow at an accelerated CAGR of 9.02% over the forecast period.

DOWNLOAD FREE SAMPLE REPORT: https://www.fiormarkets.com/report-detail/407138/request-sample

Major players in the global diphtheria, pertussis, and tetanus (DTaP) vaccine market are GlaxoSmithKline, Sanofi Pasteur, Protein Sciences Corporation, Novartis AG, Merch Sharp & Dohme Corp., Pfizer Inc., Astellas Pharma US, Sanofi Aventis, AstraZeneca, and Emergent Biosolution Inc. among others. Witnessing the potential of vaccines the regulatory bodies are progressively granting the approvals for the for the DTaP vaccines. For istance in 2017, US FDA granted its stamp of approval for the Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus, or DTaP-IPV.

The product type segment consists of Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. Kinrix is a combined diphtheria toxoid, tetanus toxoid, acellular pertussis and inactivated poliomyelitis vaccine (DTaP-IPV). Clinical trials have shown Kinrix to be immunogenic in 4-6-year-old children, with a safety profile comparable with that of separate DTaP and IPV vaccination. As a result the Kinrix segment is anticipated to grow at the highest CAGR of 8.89% over the forecast period. Disease type is segmented into diphtheria, tetanus, and pertussis. The pertussis segment led the global DTaP vaccine market with a market share of 48.73% in 2018. Growing incidence of childhood pertussis was the primary driving factor behind this increased market share. The end user segment is divided into hospitals, clinics and vaccination centers. There has been global push for bringing more and more children under the vaccination umbrella. World Bank, local governments along with CSR foundations taking forward this cause.  Thus, the vaccination centers segment is expected to grow at the highest CAG of 8.98% over the forecast period.

Even though the factors such as growing demand for DTaP vaccine, rising Incidences of diphtheria, tetanus and pertussis as well as rising awareness pertaining the advantages of  inoculation are driving the global diphtheria, pertussis, and tetanus (DTaP) vaccine market, the scattered incidences of vaccines causing injuries and stringent regulatory approval process are expected to restrain the market growth over the forecast period.

ACCESS FULL REPORT: https://www.fiormarkets.com/report/diphtheria-pertussis-and-tetanus-dtap-vaccine-market-by-407138.html

About the report:
The global diphtheria, pertussis, and tetanus (DTaP) vaccine market is analyzed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter’s five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report:
The report can be customized as per client requirements. For further queries, you can contact us on sales@fiormarkets.com or +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact Us
Mark Stone
Phone: +1-201-465-4211
Email: sales@fiormarkets.com
Web:www.fiormarkets.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.